BioCentury
ARTICLE | Company News

Abbott submits NDA

June 2, 2000 7:00 AM UTC

ABT submitted an NDA to the FDA seeking accelerated approval to market its ABT-378/r lopinavir/ritonavir combination HIV protease inhibitor to treat HIV infection and AIDS based on ongoing Phase II/II...